The Female Health Company (“FHC” or the “Company”) manufactures, markets and sells the FC2 female condom, the only currently available product under a woman’s control that is approved by the U.S. Food and Drug Administration (FDA), which provides dual protection against unintended pregnancy and sexually transmitted infections (“STIs”), including HIV/AIDS. In October 2009, the Company completed the transition from its first generation product, FC1, to its second generation product, FC2, and production of FC1 ceased. Although FC1 production has ceased, the Company retains ownership of certain world-wide rights to FC1, as well as various patents, regulatory approvals and other intellectual property related to FC1.The Female Health Company is publicly traded on the NASDAQ-CM stock exchange under the symbol "FHCO".
FC Female Condoms (FC) have undergone extensive testing for efficacy, safety and acceptability in the United States and many countries around the world. Certain studies have shown that having FC available allows women and men to access more prevention options and results in an increase in protected sex acts and a decrease in STIs, including HIV/AIDS. FC has high acceptability among both men and women in many countries.
The Female Health Company has led the female condom industry for over 25 years, engaging in research and development which resulted in safe, effective female condoms produced in compliance with stringent regulatory standards globally. FHC’s high quality products have established the industry’s standards for excellence and are the trusted choice of public health professionals and consumers worldwide. To ensure that FHC’s products are readily identifiable to its customers, the Company has recently introduced its FC2 Brand Seal. The seal, which is now included on all FC2 Female Condom packaging worldwide, certifies that the product meets the Company’s proven safety and effectiveness standards.
The FC2 Female Condom® (FC2) is available in the United States and about 138 countries around the world. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., the European Union, Canada, Australia, the Republic of South Africa. Japan, the People’s Republic of China, Spain, Mexico, Greece, Turkey and by the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Uganda, Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various other countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted infections (including HIV/AIDS), and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.